Equillium Q4 2025 revenue $0, net loss $3.8M; cash runway into 2029 after $35M financing

Equillium, Inc.

Q4 2025 revenue $0 (vs $4.4M Q4 2024); FY2025 revenue $0 (vs $41.1M FY2024 from Ono deal).
Net loss Q4 2025 $3.8M ($0.04/share); full year 2025 loss $22.4M ($0.39/share), up from $8.1M loss in 2024.
Cash & equivalents $30.3M at Dec 31, 2025; plus $35M private placement from RA Capital in March 2026.
EQ504 Phase 1 proof-of-mechanism study expected to start mid-2026 with data ~6 months later.
Company believes cash runway funds planned operations into 2029.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Equillium, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.

Period: fourth quarter and fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 25, 2026, Equillium, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-124107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.